NCT00934570

Brief Summary

The purpose of this study is to assess the sustainability of a two-year intervention aimed at improving body mass index (BMI) and metabolic and vascular health in obese youth. The study will compare lifestyle changes with diet and exercise alone with changes in lifestyle in combination with metformin medication. An initial intensive exercise program will also be compared with a standard exercise program. Hypothesis: Metformin therapy in combination with intensive lifestyle intervention in obese children and adolescents will be associated with reduced rate of weight gain, improved BMI, body composition, physical activity, physical fitness, insulin sensitivity, blood lipid profiles, adipocytokines and vascular function.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4 obesity

Timeline
Completed

Started Apr 2009

Typical duration for phase_4 obesity

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2009

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 6, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 8, 2009

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
Last Updated

October 4, 2012

Status Verified

October 1, 2012

Enrollment Period

3.1 years

First QC Date

July 6, 2009

Last Update Submit

October 3, 2012

Conditions

Keywords

ObesityMetforminPhysical activityCardiovascular health

Outcome Measures

Primary Outcomes (1)

  • Reduction in BMI

    2 years

Secondary Outcomes (1)

  • Improvement in physical activity

    2 years

Study Arms (4)

Metformin, Standard exercise

ACTIVE COMPARATOR

Lifestyle intervention with metformin and standard exercise program.

Drug: Metformin and standard exercise

Placebo, Standard exercise

PLACEBO COMPARATOR

Lifestyle intervention with placebo and standard exercise program

Behavioral: Placebo Standard exercise

Metformin, Intensive exercise

ACTIVE COMPARATOR

Lifestyle intervention with metformin and intensive exercise

Drug: Metformin Intensive exercise

Placebo, Intensive exercise

PLACEBO COMPARATOR

Lifestyle intervention with placebo and intensive exercise program.

Behavioral: Intensive exercise

Interventions

Metformin 1500 mg daily for 2 years

Also known as: GlumetzaTM 500 mg Extended Release
Metformin, Standard exercise

Metformin 1500 mg daily for 2 years

Also known as: GlumetzaTM 500 mg Extended Release
Metformin, Intensive exercise

Standard exercise

Placebo, Standard exercise

Placebo Intensive exercise

Placebo, Intensive exercise

Eligibility Criteria

Age10 Years - 16 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Obese adolescents defined as BMI greater than the 95th percentile for age and gender
  • Metformin naive subjects

You may not qualify if:

  • Elevated fasting plasma glucose ≥ 6.0 mmol/L
  • hour plasma glucose ≥ 11.1 mmol/L after a standard glucose load
  • A1C \> 6.0%
  • Medication other than "over the counter" drugs, oral contraceptive pill or thyroid hormone replacement
  • Smoking
  • Pregnancy
  • Renal insufficiency (serum creatinine \> the upper limit of normal)
  • Hepatic dysfunction (\> 1.5 times the upper limit of normal for AST and ALT)
  • Latex Allergy
  • Hypersensitivity to metformin or its ingredients
  • Breast feeding
  • Subjects with a history of lactic acidosis
  • Abnormal creatinine clearance
  • HIV, HBV, and HCV infections
  • Drug and alcohol abuse
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital, London Health Sciences Centre

London, Ontario, N6A 5W9, Canada

Location

Related Publications (2)

  • Clarson CL, Brown HK, De Jesus S, Jackman M, Mahmud FH, Prapavessis H, Robinson T, Shoemaker JK, Watson M, Dowd AJ, Hill DJ. Effects of a Comprehensive, Intensive Lifestyle Intervention Combined with Metformin Extended Release in Obese Adolescents. Int Sch Res Notices. 2014 Nov 10;2014:659410. doi: 10.1155/2014/659410. eCollection 2014.

  • Wilson AJ, Prapavessis H, Jung ME, Cramp AG, Vascotto J, Lenhardt L, Shoemaker JK, Watson M, Robinson T, Clarson CL. Lifestyle modification and metformin as long-term treatment options for obese adolescents: study protocol. BMC Public Health. 2009 Nov 30;9:434. doi: 10.1186/1471-2458-9-434.

Related Links

MeSH Terms

Conditions

ObesityDiabetes Mellitus, Type 2Motor Activity

Interventions

Metformin

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System DiseasesBehavior

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic Chemicals

Study Officials

  • Cheril Clarson, MD

    London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr Cheril Clarson

Study Record Dates

First Submitted

July 6, 2009

First Posted

July 8, 2009

Study Start

April 1, 2009

Primary Completion

May 1, 2012

Study Completion

May 1, 2012

Last Updated

October 4, 2012

Record last verified: 2012-10

Locations